Mortalin [also known as
heat shock protein family A (HSP70) member 9 (HSPA9) or
glucose-regulated
protein 75 (
GRP75)] is a mitochondrial
molecular chaperone that is often up-regulated and mislocalized in
tumors with abnormal activation of the
kinases MEK and ERK. Here, we found that
mortalin depletion was selectively lethal to
tumor and immortalized normal cells expressing the mutant
kinase B-RafV600E or the chimeric
protein ΔRaf-1:ER and that
MEK-ERK-sensitive regulation of the
peptide-binding domain in
mortalin was critical to cell survival or death. Proteomics screening identified
adenine nucleotide translocase 3 (ANT3) as a previously unknown
mortalin substrate and cell survival/death effector. Mechanistically, increased
MEK-ERK signaling activity and
mortalin function converged opposingly on the regulation of mitochondrial permeability. Specifically, whereas
MEK-ERK activity increased mitochondrial permeability by promoting the interaction between ANT3 and the peptidyl-
prolyl isomerase cyclophilin D (CypD),
mortalin decreased mitochondrial permeability by inhibiting this interaction. Hence,
mortalin depletion increased mitochondrial permeability in
MEK-ERK-deregulated cells to an extent that triggered cell death. HSP70 inhibitor derivatives that effectively inhibited
mortalin suppressed the proliferation of B-RafV600E
tumor cells in culture and in vivo, including their B-Raf inhibitor-resistant progenies. These findings suggest that targeting
mortalin has potential as a selective therapeutic strategy in B-Raf-mutant or
MEK-ERK-driven
tumors.